BRPI0412314A - derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina - Google Patents

derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina

Info

Publication number
BRPI0412314A
BRPI0412314A BRPI0412314-0A BRPI0412314A BRPI0412314A BR PI0412314 A BRPI0412314 A BR PI0412314A BR PI0412314 A BRPI0412314 A BR PI0412314A BR PI0412314 A BRPI0412314 A BR PI0412314A
Authority
BR
Brazil
Prior art keywords
pyrimidine
receptor antagonists
releasing hormone
gonadotropin releasing
hormone receptor
Prior art date
Application number
BRPI0412314-0A
Other languages
English (en)
Inventor
Zhiqiang Guo
Yongsheng Chen
Dongpei Wu
Chen Chen
Warren Wade
Wesley J Dwight
Charles Q Huang
Fabio C Tucci
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34079121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0412314(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of BRPI0412314A publication Critical patent/BRPI0412314A/pt
Publication of BRPI0412314B1 publication Critical patent/BRPI0412314B1/pt
Publication of BRPI0412314B8 publication Critical patent/BRPI0412314B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

"DERIVADOS DE PIRIMIDINA-2,4-DIONA COMO AXTAGONISTAS DE RECEPTOR DE HORMÈNIO LIBERADOR DE GONADOTROPINA". São descritos antagonistas de receptor de GnRH, os quais têm utilidade no tratamento de uma variedade de condições relacionadas a hormónios sexuais, tanto em homens como em mulheres. Os compostos dessa invenção têm a estrutura: em que R~ 1a~, R~ 1b~, R~ 1c~, R~ 2a~, R~ 2b~, R~ 3~, R~ 4~, R~ 5~, R~ 6~, e X são como definidos aqui, incluindo estereoisómeros, pró-drogas e sais farmaceuticamente aceitáveis destes. São também descritas composições contendo um composto dessa invenção em combinação com um veiculo farmaceuticamente aceitável, bem como métodos relacionados ao uso das mesmas para antagonizar hormónio liberador de gonadotropina em um paciente que necessite destes.
BRPI0412314A 2003-07-07 2004-07-06 composto 3-[2(r)-{hidroxicarbonilpropil-amino}-2-feniletil]-5-(2-flúor-3-metoxifenil)-1-[2-flúor-6-(trifluorometil)benzil]-6-metil-pirimidina-2,4(1h,3h)-diona, composição farmacêutica compreendendo dito composto e uso do mesmo para o tratamento de uma condição relacionada ao hormônio sexual BRPI0412314B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48543403P 2003-07-07 2003-07-07
US60/485,434 2003-07-07
PCT/US2004/021593 WO2005007165A1 (en) 2003-07-07 2004-07-06 Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists

Publications (3)

Publication Number Publication Date
BRPI0412314A true BRPI0412314A (pt) 2006-08-22
BRPI0412314B1 BRPI0412314B1 (pt) 2019-03-06
BRPI0412314B8 BRPI0412314B8 (pt) 2021-05-25

Family

ID=34079121

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412314A BRPI0412314B8 (pt) 2003-07-07 2004-07-06 composto 3-[2(r)-{hidroxicarbonilpropil-amino}-2-feniletil]-5-(2-flúor-3-metoxifenil)-1-[2-flúor-6-(trifluorometil)benzil]-6-metil-pirimidina-2,4(1h,3h)-diona, composição farmacêutica compreendendo dito composto e uso do mesmo para o tratamento de uma condição relacionada ao hormônio sexual

Country Status (24)

Country Link
US (3) US7056927B2 (pt)
EP (1) EP1646389B1 (pt)
JP (2) JP4722844B2 (pt)
KR (1) KR101139148B1 (pt)
CN (1) CN100424078C (pt)
AT (1) ATE407679T1 (pt)
AU (1) AU2004257639B2 (pt)
BR (1) BRPI0412314B8 (pt)
CA (1) CA2531508C (pt)
CY (1) CY1108656T1 (pt)
DE (1) DE602004016516D1 (pt)
DK (1) DK1646389T3 (pt)
EA (1) EA010370B1 (pt)
ES (1) ES2314448T3 (pt)
HR (1) HRP20080646T3 (pt)
IL (1) IL172833A (pt)
MX (1) MXPA06000297A (pt)
NO (1) NO334897B1 (pt)
NZ (1) NZ544747A (pt)
PL (1) PL1646389T3 (pt)
PT (1) PT1646389E (pt)
SI (1) SI1646389T1 (pt)
WO (1) WO2005007165A1 (pt)
ZA (1) ZA200600475B (pt)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1255738B1 (en) * 2000-01-25 2012-03-07 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
EP1644342B1 (en) * 2003-07-07 2012-05-09 Neurocrine Biosciences, Inc. Arylpyrimidines useful for the treatment of sex hormone-related conditions such as endometriosis, prostate cancer and the like
CN100376246C (zh) * 2003-07-07 2008-03-26 纽罗克里生物科学有限公司 作为促性激素释放激素受体拮抗剂的嘧啶-2,4-二酮衍生物
WO2005007165A1 (en) * 2003-07-07 2005-01-27 Neurocrine Biosciences, Inc. Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
MXPA06010571A (es) * 2004-03-15 2007-02-16 Takeda Pharmaceutical Inhibidores de dipeptidil peptidasa.
ES2534573T3 (es) 2007-04-06 2015-04-24 Neurocrine Biosciences, Inc. Antagonistas del receptor de la hormona liberadora de gonadotropina y métodos relacionados con los mismos
CL2008000986A1 (es) 2007-04-06 2008-10-17 Neurocrine Biosciences Inc COMPUESTO DERIVADO DE HETEROCICLOS DE NITROGENO, AGONISTAS DEL RECEPTOR GnRH; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHO COMPUESTO; Y USO PARA TRATAR UNA AFECCION RELACIONADA CON LAS HORMONAS SEXUALES, ENDOMETRIOSIS, DISMENORREA, ENFERMEDAD DE OV
KR101666228B1 (ko) 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
US8765948B2 (en) * 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
EP2390250B1 (en) * 2009-11-20 2015-08-12 Sk Chemicals Co., Ltd. Gonadotropin releasing hormone receptor antagonists, manufacturing method thereof, and pharmaceutical composition containing same
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
EP2881391A1 (en) 2013-12-05 2015-06-10 Bayer Pharma Aktiengesellschaft Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
EP3185881B1 (en) 2014-08-26 2022-03-09 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
US20190321363A1 (en) * 2016-06-20 2019-10-24 Dr. Reddy's Laboratories Limited Process for the preparation of elagolix sodium and its polymorph
WO2018015497A2 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
BR112019003260B1 (pt) 2016-08-23 2022-07-12 Swan Analytische Instrumente Ag Dispositivo para a eletrodeionização de um líquido de amostra, câmara de tratamento para o uso em um dispositivo e método de eletrodeionização de um lí-quido de amostra para execução em um dispositivo
TWI855377B (zh) 2016-09-30 2024-09-11 瑞士商麥歐文科學有限公司 治療女性不孕症之方法
DK3518932T3 (da) 2016-09-30 2025-01-27 Takeda Pharmaceuticals Co Behandling af prostatacancer
SMT202200254T1 (it) 2016-09-30 2022-07-21 Takeda Pharmaceuticals Co Metodi di trattamento di fibromi uterini ed endometriosi
CN110312517A (zh) * 2016-12-14 2019-10-08 普渡研究基金会 促黄体激素释放激素受体(lhrh-r)缀合物及其用途
CA3059815C (en) 2017-04-12 2020-10-27 Sandoz Ag Acid addition salts of an orally available gonadotropin-releasing hormone receptor antagonist, elagolix
EP3388421B1 (en) 2017-04-13 2019-12-04 Sandoz AG Acid addition salts of an orally available gonadotropin-releasing hormone receptor antagonist
EP3388422B1 (en) 2017-04-13 2019-11-20 Sandoz AG Amorphous solid dispersion of an orally available gonadotropin-releasing hormone receptor antagonist
WO2018198086A1 (en) * 2017-04-28 2018-11-01 Lupin Limited Process for the preparation of elagolix and pharmaceutically acceptable salts thereof
EP3634418A1 (en) 2017-06-05 2020-04-15 ObsEva S.A. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
WO2018224063A2 (en) * 2017-06-08 2018-12-13 Zentiva, K.S. Solid forms of elagolix
WO2019036712A1 (en) 2017-08-18 2019-02-21 Abbvie Inc. PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME OR ADENOMYOSIS
KR20200109291A (ko) * 2017-08-18 2020-09-22 애브비 인코포레이티드 자궁내막증, 자궁섬유증, 다낭난소증후군 또는 샘근육증을 치료하기 위한 약제학적 제형
US12083227B2 (en) 2017-08-18 2024-09-10 Abbvie Inc. Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
CN107935863A (zh) * 2017-11-30 2018-04-20 厦门海乐景生化有限公司 Elagolix的关键原料化合物C的合成方法
JP7200261B2 (ja) * 2017-12-05 2023-01-06 スージョウ ポンシュー ファーマテック カンパニー リミテッド エラゴリクスを作製するプロセス
CN110938037A (zh) * 2018-09-21 2020-03-31 苏州鹏旭医药科技有限公司 一种依拉戈利钠盐药物中间体的制备方法
WO2019115019A1 (en) 2017-12-11 2019-06-20 Synthon B.V. Process for preparing elagolix
CN109970663B (zh) * 2017-12-27 2023-04-11 上海科胜药物研发有限公司 一种制备噁拉戈利中间体的方法
CN108129400B (zh) * 2017-12-29 2021-10-15 安帝康（无锡）生物科技有限公司 氘代噁拉戈利衍生物及其用途
AU2018419533A1 (en) 2018-04-19 2020-11-12 Abbvie Inc. Methods of treating heavy menstrual bleeding
CN110669013A (zh) * 2018-07-03 2020-01-10 江苏海悦康医药科技有限公司 一种噁拉戈利中间体的制备方法
CN112469417A (zh) * 2018-07-23 2021-03-09 艾伯维公司 恶拉戈利钠组合物和方法
JP2021532160A (ja) * 2018-08-01 2021-11-25 アッヴィ・インコーポレイテッド エラゴリックスに関する投与計画
EP3572406A1 (en) 2018-10-17 2019-11-27 Sandoz Ag Acid addition salt of elagolix and related compounds
WO2020089190A2 (en) 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
KR20210100623A (ko) 2018-11-07 2021-08-17 옵스에파 에스에이 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법
CN109293634A (zh) * 2018-12-04 2019-02-01 中国药科大学 恶拉戈利杂质的制备方法
CN109651171A (zh) * 2019-01-13 2019-04-19 苏州鹏旭医药科技有限公司 依拉戈利及其钠盐的中间体及其盐的制备方法和应用
AU2020209646A1 (en) 2019-01-15 2021-08-26 Lupin Inc. Deuterated elagolix-like compositions and methods
CN109810065B (zh) * 2019-02-16 2022-07-15 安徽华胜医药科技有限公司 一种恶拉戈利的合成方法
CN109651265A (zh) * 2019-02-16 2019-04-19 安徽诺全药业有限公司 一种Elagolix的制备方法
CN109761913A (zh) * 2019-02-16 2019-05-17 安徽华胜医药科技有限公司 一种有机金属钯催化合成elagolix中间体的方法
CN110041232A (zh) * 2019-04-10 2019-07-23 丽珠集团新北江制药股份有限公司 一种制备GnRHR药物关键中间体化合物的方法
CN109956906B (zh) * 2019-04-19 2021-01-29 奥锐特药业股份有限公司 一种噁拉戈利关键中间体的制备方法
US20220242831A1 (en) * 2019-05-24 2022-08-04 Dr. Reddy's Laboratories Limited Improved process for the preparation of elagolix and its intermediates
CN110204498B (zh) * 2019-06-14 2020-11-27 奥锐特药业股份有限公司 一种高效合成噁拉戈利中间体的方法
CN110372608A (zh) * 2019-07-09 2019-10-25 丽珠集团新北江制药股份有限公司 一种促性腺激素释放激素拮抗剂的制备方法
ES2802815B2 (es) 2019-07-12 2022-03-14 Moehs Iberica Sl Sal clorhidrato de 3-[2(r)-amino-2-feniletil]-5-(2-fluoro-3-metoxifenil)-1-[2-fluoro-6-(trifluorometil)bencil]-6-metil-1h-pirimidin-2,4(1h,3h)-diona (i) en forma solida, procedimiento para su preparacion y uso de la misma en la sintesis de elagolix
CN110372609B (zh) * 2019-07-25 2021-04-09 奥锐特药业股份有限公司 一种噁拉戈利钠盐的纯化方法
CN112672998B (zh) 2019-07-31 2022-06-21 深圳仁泰医药科技有限公司 恶拉戈利与乙胺嘧啶的共晶型a及其制备方法和用途
KR20220061120A (ko) 2019-08-08 2022-05-12 옵스에파 에스에이 에스트로겐-의존성 장애 치료용 조성물 및 방법
US20220288154A1 (en) 2019-08-08 2022-09-15 ObsEva S.A. Gnrh antagonists for the treatment of estrogen-dependent disorders
IT202000001390A1 (it) 2020-01-24 2021-07-24 Ind Chimica Srl Processo per la preparazione del sale sodico dell’acido 4-[[(1r)-2-[5-(2-fluoro-3-metossifenil)-3-[[2-fluoro-6-(trifluorometil)fenil]metil]-3,6-diidro-4-metil-2,6-diosso-1(2h)-pirimidinil]-1-feniletil]ammino]-butanoico (elagolix sale sodico) e intermedi di detto processo
AU2020340670A1 (en) 2019-09-03 2022-04-07 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
IT201900015458A1 (it) 2019-09-03 2021-03-03 Ind Chimica Srl Processo per la preparazione del sale sodico dell’acido 4-[[(1r)-2-[5-(2-fluoro-3-metossifenil)-3-[[2-fluoro-6-(trifluorometil)fenil]metil]-3,6-diidro-4-metil-2,6-diosso-1(2h)-pirimidinil]-1-feniletil]ammino]-butanoico (elagolix sale sodico) e intermedi di detto processo
WO2021044230A1 (en) * 2019-09-03 2021-03-11 Industriale Chimica S.R.L. Process for the synthesis of the sodium salt of 4-[[(lr)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-l(2h)-pyrimidinyl]-l- phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process
TWI755055B (zh) * 2019-09-18 2022-02-11 台灣神隆股份有限公司 用於製備惡拉戈利鈉及其中間體的方法
WO2021064561A1 (en) * 2019-10-03 2021-04-08 Neuland Laboratories Limited An improved process for the preparation of elagolix sodium
CN112694445B (zh) * 2019-10-22 2023-07-28 成都倍特药业股份有限公司 一种噁拉戈利钠中间体的纯化方法
ES2822398B2 (es) * 2019-10-30 2022-03-02 Moehs Iberica Sl 3-((R)-2-(Amino-2-feniletil)-1-(2-fluoro-6-trifluorometilbencil)-5-yodo-6-metil-1H-pirimidin-2,4-diona o una sal de la misma, procedimiento para su preparación y su uso en la síntesis de elagolix
WO2021130776A1 (en) * 2019-12-27 2021-07-01 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of 4-({(1 r)-2-[5-(2-fluoro-3methoxyphenyl)-3-{[2-fluoro-6-(trifluoro methyl) phenyl]methyl}-4-methyl-2,6-dioxo-3,6dihydropyrimidin-1(2 h)-yl]-1-phenylethyl}amino)butanoic acid or its pharmaceutically acceptable salts
CN113125575B (zh) * 2019-12-31 2023-04-18 济南尚博生物科技有限公司 一种1-(2-氟-6-(三氟甲基)苄基)-6-甲基嘧啶-二酮的定量分析方法
CN111116490A (zh) * 2020-01-15 2020-05-08 奥锐特药业股份有限公司 一种噁拉戈利中间体水杨酸盐的制备与纯化方法
WO2021160597A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
IL296196A (en) * 2020-03-05 2022-11-01 Abbvie Inc Methods of administering elagolix
WO2021180862A1 (en) 2020-03-12 2021-09-16 Synthon B.V. Pharmaceutical compositions comprising elagolix sodium
CN111333548B (zh) * 2020-04-10 2022-04-26 江苏海悦康医药科技有限公司 1-(2-氟-6-(三氟甲基)苄基)脲的制备方法
CN113527213B (zh) 2020-04-20 2023-01-03 上海英诺富成生物科技有限公司 促性激素释放激素受体拮抗剂及其用途
CN113683572A (zh) * 2020-05-18 2021-11-23 陈晓雯 噁拉戈利的中间体及其制备方法和应用
MX2022015003A (es) 2020-05-29 2023-03-03 Myovant Sciences Gmbh Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina.
CN113880773A (zh) * 2020-07-02 2022-01-04 南京药石科技股份有限公司 一种噁拉戈利中间体的制备方法
CN112457258A (zh) * 2020-11-26 2021-03-09 诚达药业股份有限公司 一种噁拉戈利钠及其中间体的制备方法
WO2022165097A1 (en) 2021-01-29 2022-08-04 Abbvie Inc. Methods of administrating elagolix
KR102656087B1 (ko) 2024-01-12 2024-04-09 주식회사 씨엠지 Led 소자의 에폭시 수지 코팅층 형성 방법
WO2026018221A1 (en) 2024-07-18 2026-01-22 ReproNovo SA Crystalline compositions for improving embryo implantation and methods of using the same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5844896A (en) 1995-06-01 1996-12-18 Takeda Chemical Industries Ltd. Tricyclic diazepines useful as gnrh receptor antagonists
CA2229205A1 (en) 1995-10-19 1997-04-24 Shuichi Furuya Thienopyridine derivatives, their productions and use
CN1200114A (zh) 1995-10-19 1998-11-25 武田药品工业株式会社 作为gnrh拮抗剂的喹啉衍生物
SK77298A3 (en) 1995-12-14 1999-01-11 Merck & Co Inc Nonpeptide derivatives, pharmaceutical composition containing them and their use
WO1997021707A1 (en) 1995-12-14 1997-06-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EE9800181A (et) 1995-12-14 1998-12-15 Merck & Co., Inc. Gonadotropiini riliisinghormooni antagonist, selle kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
WO1997021435A1 (en) 1995-12-14 1997-06-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1998055470A1 (en) 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP1011667A4 (en) 1997-06-05 2001-03-28 Merck & Co Inc GONADOTROPHIN RELEASING HORMON ANTAGONISTS
WO1998055116A1 (en) 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP0986557A4 (en) 1997-06-05 2001-03-14 Merck & Co Inc GONADOTROPIN RELEASING HORMON ANTAGONISTS
US6313301B1 (en) 1997-08-13 2001-11-06 Takeda Chemical Industries, Ltd. Thienopyridine derivatives, their intermediates and production thereof
CA2372044A1 (en) 1999-05-14 2000-11-23 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
US20020065309A1 (en) 1999-08-04 2002-05-30 Ge Peng Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists
EP1220857B1 (en) 1999-10-15 2005-09-21 Neurocrine Biosciences, Inc. Gonadotropin releasing hormone receptor antagonists and their related methods of use
EP1255738B1 (en) * 2000-01-25 2012-03-07 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
SE0100566D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
AU2002324586B2 (en) 2001-08-02 2008-04-24 Neurocrine Biosciences, Inc. 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
KR20040030893A (ko) 2001-08-02 2004-04-09 뉴로크린 바이오사이언시즈 인코퍼레이티드 치환된 피리딘-4-온 및 고나도트로핀 분비 호르몬 수용체길항제로서의 이의 용도
EP1411941A2 (en) 2001-08-02 2004-04-28 Neurocrine Biosciences, Inc. Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
EP1412363A1 (en) 2001-08-02 2004-04-28 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists
KR20040023712A (ko) 2001-08-02 2004-03-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 고나도트로핀 분비 호르몬 수용체(ｇｎｒｈ) 길항제로서의1,2,4-트리아진-3,5-디온
WO2005007165A1 (en) * 2003-07-07 2005-01-27 Neurocrine Biosciences, Inc. Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
EP1644342B1 (en) 2003-07-07 2012-05-09 Neurocrine Biosciences, Inc. Arylpyrimidines useful for the treatment of sex hormone-related conditions such as endometriosis, prostate cancer and the like
CN100376246C (zh) 2003-07-07 2008-03-26 纽罗克里生物科学有限公司 作为促性激素释放激素受体拮抗剂的嘧啶-2,4-二酮衍生物

Also Published As

Publication number Publication date
CA2531508A1 (en) 2005-01-27
US20070191403A1 (en) 2007-08-16
DE602004016516D1 (de) 2008-10-23
HRP20080646T3 (en) 2009-01-31
JP4722844B2 (ja) 2011-07-13
PL1646389T3 (pl) 2009-03-31
US7419983B2 (en) 2008-09-02
WO2005007165A1 (en) 2005-01-27
ATE407679T1 (de) 2008-09-15
CN1819829A (zh) 2006-08-16
US7176211B2 (en) 2007-02-13
US20060122202A1 (en) 2006-06-08
KR20060031851A (ko) 2006-04-13
MXPA06000297A (es) 2006-03-28
ES2314448T3 (es) 2009-03-16
EA010370B1 (ru) 2008-08-29
ZA200600475B (en) 2007-04-25
JP5226760B2 (ja) 2013-07-03
CN100424078C (zh) 2008-10-08
AU2004257639A1 (en) 2005-01-27
US20050038057A1 (en) 2005-02-17
JP2007521309A (ja) 2007-08-02
DK1646389T3 (da) 2009-01-05
SI1646389T1 (sl) 2009-02-28
EP1646389B1 (en) 2008-09-10
IL172833A (en) 2011-03-31
EP1646389A1 (en) 2006-04-19
KR101139148B1 (ko) 2012-04-26
CA2531508C (en) 2013-10-08
PT1646389E (pt) 2008-12-19
CY1108656T1 (el) 2014-04-09
IL172833A0 (en) 2006-06-11
EA200600190A1 (ru) 2006-08-25
JP2011088902A (ja) 2011-05-06
BRPI0412314B8 (pt) 2021-05-25
NO20056251L (no) 2006-01-31
US7056927B2 (en) 2006-06-06
NZ544747A (en) 2009-06-26
BRPI0412314B1 (pt) 2019-03-06
NO334897B1 (no) 2014-06-30
AU2004257639B2 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
BRPI0412314A (pt) derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
BRPI0412327A (pt) derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
BRPI0809931B8 (pt) antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo
CY1112815T1 (el) Ανταγωνιστες υποδοχεα ορμονης απελευθερωσης γοναδοτροπινης και μεθοδοι που σχετιζονται με αυτους
BR0016166A (pt) Compostos de diidropirimidina heterocìclicos
WO2005042516A3 (en) Ligands of melanocortin receptors and compositions and methods related thereto
ATE249214T1 (de) Pentafluorobenzensulfonamide und analoge
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
DE60045508D1 (de) Dalda-analoge und ihre verwendung
DE60022769D1 (de) Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen
DK1129091T3 (da) Antagonister for CRF-receptorer og fremgangsmåder med relation dertil
EA200200831A1 (ru) Фармацевтическая композиция, включающая пеметрексед вместе с монотиоглицерином, l-цистеином или тиогликолевой кислотой
BR0007864A (pt) Composto, e, uso de um composto
BRPI0414643A (pt) composto, composições farmacêuticas, e, uso de um composto
DE60208803D1 (de) 1,3,5-triazine-2,4,6-trione, herstellung und anwendungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren
BRPI0511979A (pt) derivados de triazóis substituìdos como antagonistas de oxitocina, composição farmacêutica compreendendo os referidos derivados, bem como uso dos mesmos
UA83870C2 (ru) Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1
BR0207886A (pt) Ciclopropa-heterociclos como inibidores de transcriptase reversa não-nucleosìdeos
PE20050207A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros referida a enfermedades dependientes de hormonas
ES2173027A2 (es) Uso de nucleotidos en el tratamiento del glaucoma y la hipertension ocular.
SE9802207D0 (sv) Novel compounds
ECSP993058A (es) Antagonistas de la hormona liberadora de gonadotropina
ECSP993074A (es) Nuevos derivados sustituidos del pirazol

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/03/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/07/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2840 DE 10/06/2025 POR TER SIDO INDEVIDA.